Results 41 to 50 of about 2,311,361 (335)
Severe organising pneumonia following COVID-19 [PDF]
Thorax, 2020 Various forms of diffuse parenchymal lung disease have been proposed as potential consequences of severe COVID‑19. We describe the clinical, radiological and histological findings of patients with COVID‑19-associated acute respiratory distress syndrome who later developed severe organising pneumonia including longitudinal follow-up.
Vadász, István +11 more
openaire +3 more sources
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
New England Journal of Medicine, 2021 Background Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered ...
R. Libster +55 more
semanticscholar +1 more source
Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination
Skin Health and Disease, 2023 Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause. We report a 67‐year‐old man with Pityriasis rubra pilaris might induced by COVID‐19 vaccination.
Ya‐ting Liu, Shang‐shang Wang
doaj +1 more source
The Functional Roles of MDSCs in Severe COVID-19 Pathogenesis
Viruses, 2023 Severe COVID-19 is a major cause of morbidity and mortality worldwide, especially among those with co-morbidities, the elderly, and the immunocompromised.
Jia Soon Len +2 more
doaj +1 more source
Rigidity of the Outer Shell Predicted by a Protein Intrinsic Disorder Model Sheds Light on the COVID-19 (Wuhan-2019-nCoV) Infectivity [PDF]
, 2020 The world is currently witnessing an outbreak of a new coronavirus spreading quickly across China and affecting at least 24 other countries. With almost 65,000 infected, a worldwide death toll of at least 1370 (as of 14 February 2020), and with the ...
Dunker, A. Keith +3 more
core +1 more source
International Journal of Antimicrobial Agents, 2020 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public ...
Chih-Cheng Lai +4 more
semanticscholar +1 more source
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
New England Journal of Medicine, 2020 Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).
J. Goldman +25 more
semanticscholar +1 more source
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
New England Journal of Medicine, 2021 Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for disease ...
R. Gottlieb +29 more
semanticscholar +1 more source
Severe thrombocytopaenia secondary to COVID-19 [PDF]
BMJ Case Reports, 2020 The SARS-CoV-2 infection has caused a pandemic with a case rate of over 290 000 lab-confirmed cases and over 40 000 deaths in the UK. There is little evidence to inform the optimal management of a patient presenting with new or relapsed acute idiopathic thrombocytopaenic purpura with concurrent SARS-CoV-2 infection.
Patel, Trupesh +3 more
openaire +2 more sources
Safety Recommendations for Evaluation and Surgery of the Head and Neck During the COVID-19 Pandemic [PDF]
, 2020 Importance The rapidly expanding novel coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has challenged the medical community to an unprecedented degree.
Chinn, Steven B. +13 more
core +1 more source